Many therapeutic modalities including continuous positive airway pressure, surgery, and oral appliances are used to treat patients with sleep-disordered breathing. However, there are no definitive treatment modalities for individual patients due to various causes of sleep-disordered breathing. Clinicians should have select best options for individual patients and it is quite challenging process. Oral appliances attracted clinical attention for its convenience and safety. Several designs of oral appliances are introduces such as soft palate lifter, tongue retaining device, and various appliances which aimed to mandibular advancement. Among these oral appliances, mandibular advancement devices (MADs) are considered the most excellent based on their effectiveness and patient tolerance. Although MADs are not guarantee dramatic outcome and less consistent than continuous positive airway pressure, they offer several advantages over continuous positive airway pressure and surgical methods, including non-invasiveness, silence, portability, and tolerability, simplicity. Therefore, general dental practitioner who had passed sleep dental curriculum or coursework can treat the patients with sleep problems. This article reviews the history, clinical indications, suggested mechanism of actions, various positive effects and several side effects, factors predicting a favorable outcome, determining amounts of mandibular advancement, compliance and long-term efficacy of MADs use.
and activates the cardiovascular system as well as the central nervous system. Furthermore, the impaired sleep quality secondary to frequent arousal causes excessive daytime sleepiness, mood change, disturbed neurocognition, chronic any significant reduction in snoring or the apnea-hypopnea index (AHI). 17) Even TRDs have significantly less effect on snoring and AHI, and also cause more patient discomfort compared to MADs 16) ; this results in poor tolerability, low compliance, and rejection by patients, although TRDs were as effective as MADs in reducing the AHI in a previous study. 18) Barthlen et al. 16) observed differing efficacy and tolerance in eight subjects in a comparison of MADs, TRDs, and SPLs.
While MADs required at least six teeth per arch to ensure proper retention, TRDs could be used in patients with less than six teeth or even no dentition. 16) The study showed that all subjects (100%) in the MAD group tolerated the appliance, while five subjects in the TRD group and only two subjects in the SPL group tolerated their respective appliances. Furthermore, MADs were significantly more effective than TRDs and SPLs in reducing the AHI.
16)

CLINICAL INDICATIONS
Based on American Academy of Dental Sleep Medicine guidelines, MADs are indicated in patients with primary snoring and mild to moderate OSA. 19) They are also recommended in patients with severe OSA, and those unable to tolerate CPAP. 20) MADs are sometimes used as an adjunct to CPAP or other therapies for a better clinical effect. 21) According to the guideline of American Sleep Disorders Association, oral appliances are indicated for patients with simple snoring or mild OSA and in patients with moderate to severe OSA who cannot tolerate or refuse CPAP therapy. 22) There were reports about the treatment outcomes according to the severities of OSA. Patients with severe OSA had less reduction in apneas (49%) than patients with mild to moderate OSA (70%). 22, 23) In addition, MADs appears to be an effective therapeutic options for treating persistent apneas patients who fail UPPP. 24) Twelve of the eighteen patients who failed UPPP were responders to MADs therapy (AHI <10).
Cephalometric studies have been used to predict outcome of MADs treatment. It is generally take for granted that a retrognathic mandible, high position of the hyoid bone, relatively normal post-palatal and post-lingual airway and narrow tongue base could be predictors for successful outcome of MADs therapy. 25) procedures such as uvulopalatopharyngoplasty (UPPP), and oral appliances. Of these treatment, oral appliances are recently paid attention from many clinicians due to its effectiveness and convenience. 7) Oral appliances for treating SDB are classified into mandibular advancement devices (MADs), tongue-retaining devices (TRDs), and soft palatal lifters (SPLs) according to the suggested mechanism of action. 8) Among them, MADs are the most frequently used due to their superior efficacy and patient tolerance, and more than 50 designs of MADs have been clinically introduced presently. 9, 10) In the present review, we summarize the history, mechanisms of action, clinical effects/side effects, determining of mandibular position, patient compliance, and long-term efficacy of MADs. 
HISTORY OF MADS AND OTHER ORAL APPLIANCES
1) Sleepiness
Effects on subjective daytime sleepiness have been mostly evaluated using the Epworth sleepiness scale (ESS). Several placebo-controlled studies revealed that subjective sleepiness decreased to almost normal or by 1-4 points after implementing MADs. [35] [36] [37] [38] The relief of SDB improved the sleep quality, manifested in the reduced mean arousal index, which is notable as sleep quality is believed to play an important role in reducing daytime sleepiness. 35) However, improved daytime sleepiness was sometimes observed without a concurrent normalization of objective respiratory indices. 35, 39) A previous study on the effects of MADs found that the ESS scores normalized in 82% of subjects, whereas snoring was completely relieved in only 23% of subjects. 35) These findings indicate that factors other than the objective respiratory indices also contribute to excessive daytime sleepiness in patients with SDB. MADs are believed to improve subjective sleepiness by altering unknown factors as well as improving respiratory parameters. MADs are similar to or less effective than CPAP in reducing daytime sleepiness. 40) Objective sleepiness has been examined using the multiple sleep latency test (MSLT), Osler test, and the maintenance of wakefulness test (MWT). A controlled study evaluating MSLT found improved objective sleepiness compared to the placebo. 35) In addition, two studies using the Osler test or MWT reported similar results 40, 41) ; otherwise, a different study reported no significant improvement in MWT. 42) MADs are considered to have a similar or lower effect on objective sleepiness in comparison with CPAP.
43)
MECHANISM OF ACTION
The exact mechanism of action of MADs remains unclear despite several previous studies; however, it is reasonable to conclude that anatomical modification in oropharynx by mandibular advancement provide the favorable circumstance during respiration. 26, 27) After using MADs, the muscle tone was altered in the masseter, submental, and genioglossus muscles of subjects, muscles likely involved in maintaining the upper airway. 28) In addition, the adjacent tissues, including the tongue and hyoid bone, were repositioned while subjects wore MADs. 29) The velopharynx and oropharynx were revealed as the primary targeted sites in the upper airway rather than the hypopharynx. [30] [31] [32] In contrast, a placebo appliance without any protrusive repositioning showed no significant upper airway widening. Therefore, mandibular protrusion is a key factor underlying the clinical mechanism of MADs. Collectively, MADs presumably stabilize and enlarge the pharyngeal airway by repositioning the soft tissue and changing the muscle tone associated with upper airway collapse.
33)
CLINICAL EFFECTS
The clinical effects of MADs are divided into their direct effects on OSA and indirect effects on the OSA-associated symptoms and complications.
Direct Effects on OSA
All previous studies showed that MADs significantly reduced objective respiratory indices such as AHI and respiratory disturbance index (RDI) compared to placebo or baseline. 34) Despite this clear outcome, previous studies also found that the reductions in respiratory indices with
MADs were both less effective and more variable than those achieved with CPAP. 34) Previous studies reported that MADs decreased the mean AHI or RDI to 4.5-34, corresponding to a mean 28%-80% reduction rate (overall mean reduction rate of 55%). 33, 34) In contrast, CPAP reduced these indices from a mean of 18-40 to 2.4-8.0, corresponding to a 74%-94% mean reduction rate (overall 83% mean reduction). 34) Therefore, to improve the clinical predictability, a careful activities. Regarding to the degree of arousal, there are several reports described the correlation between using MADs and neuro-responsiveness. A previous study reported that the use of MADs for 2-3 months improved the simulated driving performance comparable to improvements observed with CPAP. 43) While improved neurocognition and decreased daytime sleepiness are expected to decrease the risk of vehicular accidents, there is no study confirming whether MADs usage actually prevents vehicular accidents.
According to Naismith et al., 37) 4 weeks use of MADs improved self-reported sleepiness, fatigue/energy levels, however, the level of attention/memory, visuospatial or executive functioning were not improved. While several studies were performed to evaluate neurocognition improvements in children/adolescents after surgery or CPAP. 50, 51) The exact effects on neurocognition in children/adolescents remain to be clearly established.
4) Quality of life
Evaluating the QOL is quit challenging because it is dependent on individuals and not easy to objectify. However, it is valuable to measure patient's subjective symptoms not Lam et al. 39) reported improved QOL based on the SAQLI, which indicates that MADs were more effective than CPAPs.
Another study reported significant improvements in mean vitality, contentment, and sleep in patients using MADs similar to those undergoing UPPP after 1 year of treatment. 52) In addition, the effects of MADs were similar or better than those of CPAP. One important considering thing when comparing self-reported QOL from different studies
2) Snoring
Snoring itself is frequently major reason why the patients come to the clinics. Non-apneic snorer without daytime sleepiness do usually not tolerate to the CPAP therapy.
Even though they agree easily and try to use the CPAP, but considerable patients will stop using the CPAP before long.
Surgical interventions are also risky to the patients of simple snoring without apnea and often cause resistance to patients due to its irreversible results. Patients who prefer noninvasive and simple methods usually select oral appliance options as first choice to solve their snoring.
Of the various oral appliances, SPL was originally invented to reduce vibration of soft tissue, however, it turned out that there is no advantages in using SPL to treat snoring. TRDs could be another option for treating the snoring. According to George, 44) snoring was decreased or completely disappeared after TRDs use. Other reports also support the effectiveness of TRDs to snoring patients in an aspect of decreased visual analogue scale and percent of loud snoring time. 45, 46) Despite of its effectiveness on snoring, TRDs have lower tolerance to the patient due to the associated adverse effects. 45) MADs are the most popular and appropriate oral appli- 
3) Neurocognition
One of main social concern of OSA is increased risk of accidents due to the dampened recognition while daytime 
OSA Severity
MADs is likely to be more effective in patients with mild is variable criteria and medical conditions of individual patient. These factors can significantly affect the subjective symptoms, interpreters and researches have to keep in mind these limitation or bias.
5) Cardiovascular symptoms
There were numerous investigations to verify the relationship between sleep apnea and cardiovascular problems, such as hypertensions, coronary artery disease, and cerebrovascular disease. Because the application of oral appliance can indicated to moderate OSA, there have been several reports to examine the effectiveness of MADs on cardiovascular symptoms in OSA patient. Significant reduction in some variables of blood pressure (BP) has been reported after treatment using MADs. 39, 42) In patients with an AHI >10, after 4 weeks of using MADs, the 24-hour diastolic BP decreased by 2 mmHg and AHI decreased compared to the placebo. 53) Another study showed a 3-mmHg BP decrease during wakefulness, but not during sleep. Yet another study observed a significant decrease in nocturnal diastolic BP but not in the 24-hour BP after MAD use for 3 months.
42)
Lam et al. 54) reported that the significantly reduced systolic BP associated with MADs was maintained during a 1-year follow-up. In addition, two studies showed a significantly reduced single BP, although the measurement method used in that study was less reliable. 39, 55) Endothelial reactivity is also likely to improve after using MADs. 34) A previous study showed similar improvements in microvascular reactivity after treatment with either MADs or CPAPs and suggested that the increased vasodilation may reflect decreased nocturnal oxygen desaturation. 56) More interestingly, after 1 year of MAD use, the improved endothelial function approached that of normal subjects. 57) Finally, Anandam et al. 58) showed in a controlled cohort study that the cardiovascular death rate was significantly and equally lower in MAD or CPAP users than in non-users, although AHI was significantly higher in MAD users than among CPAP users.
CONSIDERATION OF PREVIOUS SUCCESS CRITERIA
Previous studies have assessed the treatment outcome using variable measures including objective respiratory 46.03% in patients with non-positional OSA. Their study also found that the positional OSA group had a higher BMI than the non-positional group did, and they surmised that the non-positional OSA patients may have a more collapsible pharyngeal airway that is possibly worsened by obesity.
62)
Anatomic Variables
Many studies have compared the anatomic differences between good and poor responders and suggest several predictive factors. Several studies have particularly focused on the efficacy of MADs according to the upper airway collapse site. MADs were reportedly more effective in OSA patients with collapse localized in the oropharynx rather than the velopharynx. 31, 32) However, the anatomic site most likely to respond to MADs has been localized to different upper airway region. A previous study found that in good responders, a larger cross-sectional area of the velopharynx was involved than that observed in poor responders. 30) Another study using MRI found a similar result. 68) Therefore, despite other similar studies reporting that the hypopharynx was likely to respond MADs, the ideal anatomic site is undetermined. In addition, certain cephalometric variables appear to affect the treatment outcome. Among them, a higher positioned hyoid bone and smaller upper airway space were closely associated with a better response to MADs.
60)
SIDE EFFECTS
Side effects caused by MADs are relatively frequent but mild in intensity. 35) Side effects occurred more frequently in subjects treated with MADs than in those treated with a placebo. 35) Typical immediate side effects include jaw discomfort, tooth tenderness, dry mouth, and excessive salivation immediately after using MADs; long-term effects include tooth movement, dry mouth, and jaw discomfort. 30) Specifically in patients experiencing occlusal alterations, previous studies reported a decreased overjet and overbite. After an average 7.3 years of using MADs, Almeida et al. 69) reported mean overbite and overjet reductions of 1.9 mm and 1.2 mm, respectively. Similarly, Marklund 70) found that both overbite and overjet decreased by 0.6 mm over a 5-year follow-up of 155 patients with OSA. However, OSA and more frequently achieves normalization in patients with mild and moderate OSA than in those with severe OSA. 36, 61) A study found that 21 of 25 patients with mild to moderate OSA normalized, while only 8 of 26 patients with severe OSA normalized when using MADs. 61) Another study reported that the rate of decrease to an AHI <10 after using MADs was 81%, 60%, and 25% in patients with mild, moderate, and severe OSA, respectively. 36, 24) However, although post-treatment AHI in most patients remained above a normal AHI, this study also found that the magnitude of the AHI decrease was greater in patients with severe OSA, from 53 to 14. 24) These findings were supported by similar findings in a relatively large study evaluating the PSG in 397 patients. 36) Both studies showed that the magnitude of the AHI decrease was significantly decreased in the severe OSA group, and normalization rate was decreased in both the moderate and severe OSA groups using MADs. 36) These findings indicate the superior outcome of CPAP compared to MADs in decreasing AHI.
Age, Gender, Obesity, and Sleep Posture Dependency
MADs are more likely to be effective in patients that are female, younger, and less obese 59, 60) ; they are also more efficacious in patients with supine position-dependent OSA. 62, 63) Liu et al. 60) showed that in subjects with a good, moderate, or poor AHI decrease, the mean body mass index (BMI) was significantly lower in those with a good outcome (mean BMI=27.26) than in those with a poor outcome (mean BMI=32.14). Previous studies suggested that excess tissues surrounding the upper airway in obese patients promoted airway collapse. In particular, truncal obesity altered the breathing pattern and reduced oxygen storage, thereby compromising effective muscle tone activation associated with mandibular advancement. 64) The better response in female patients may reflect their comparatively greater pharyngeal enlargement during mandibular advancement, as well as their stiffer and less collapsible airway. 63, 65, 66) Treatment outcome disparities associated with age may be explained by the decreased ability of respiratory muscles to generate tension and resist fatigue, increasing the ventilatory instability during sleep. 60, 67) In a study of posturedependent OSA, Chung et al. 62) reported that MADs reduced AHI by 74.69% in patients with positional OSA, but only 
PREFERENCE AND COMPLIANCE
MADs are strongly preferred to CPAP or placebo appliances by most of patients. 48) A previous study found that 81% of patients selected MADs, whereas only 19% selected CPAP. 85) The high preference is another advantage of MADs, which were portable, silent, and better tolerated than CPAP therapy, and more effective than a placebo appliances. Contrary to most previous studies, one study reported a slightly higher preference for CPAP than MADs. 42) In this randomized controlled crossover trial of 3 months of treatment, post-treatment AHI was significantly lower in patients using CPAP than in those using MADs. 42) Therefore, the patient preference appeared to depend on not only comfort but also effectiveness. 86) Based on self-reports by patients, short-term compliance reached 76%-95%, which is higher than that observed in CPAP. 34) However, compliance decreased over time, declining from 76% in the first year to there was no alteration in the condylar shape after using
MADs for 1 year. 71) These findings suggest that the occlusal change was caused by teeth migration rather than condylar change. Furthermore, these occlusal alterations were considered mild and favorable and are not generally linked to disturbed mastication. 72) Other side effects were usually relieved by symptomatic treatment, temporary cessation and, if needed, further adjustment of the device. The frequency of side effects associated with MADs is similar to that associated with CPAP. 40) Therefore, periodic follow-up is needed to manage potential side effects or discomfort.
DETERMINING THE THERAPEUTIC POSITION OF THE MANDIBLE
The mandibular position is directed forward and downward in patients using MADs.
Increasing the mouth opening from 4 to 14 mm did not significantly affect the AHI. 73) Contrary to this finding, another study showed that increasing the vertical dimension (VD) without mandibular protrusion aggravated AHI in approximately 50% of subjects. 74) In addition, increased VD enhanced temporomandibular symptoms and decreased patient preference. 73) Therefore, unnecessary increases in VD are not recommended.
While the optimal mandibular protrusion for managing OSA and snoring depends on the individual patient, mandibular protrusion appears to have a dose-dependent nonlinear association with decreasing AHI and increasing frequency of side effects. 75) Reportedly, patients with 50%-75% of maximum mandibular protrusion had a more than 25% AHI decrease. 75, 76) However, the side effect prevalence increased significantly beyond 50% of maximum mandibular protrusion. 76) Therefore, the beginning at 50% of maximum mandibular protrusion may be best, though this was not confirmed. In addition, the protrusion range had less effect on patients with mild and moderate than those with severe OSA.
77)
COMPARISON BETWEEN DIFFERENT TYPES OF MADS
There are a few studies comparing different MADs. Nonadju stable MADs were considered less practical because the time advances. 83) As oral appliances are applied to more OSA patients, the need of long-term efficacy data will be growing. approximately 50% in the second to fourth years. 34, 83) One review article revealed that despite the high initial compliance, the compliance of MADs was likely to decrease more sharply than CPAP use, approaching a similar compliance to that of long-term use of CPAP. 87) Patients who ceases the MADs mostly pointed out its ineffectiveness and discomfort. Therefore, the clinician must have reevaluate the condition of MADs to maintain compliances, including routine examinations and adjustment, along with repetitive patient education. 49, 83) 
CONCLUSIONS
LONG-TERM EFFICACY
Because of OSA treatment is a lifelong process, long-term follow-up is important when it comes to evaluating success or failures of treatment and compliance. However, there are few long-term follow-up studies to evaluate the efficacy of treatment. Previous studies found that the initial drop in AHI with MADs was usually maintained or slightly increased over time. Another study showed that MADs were still able to effectively decrease AHI after 2 years despite an increased subjective daytime sleepiness. 83) Increased subjective sleepiness may reflect the tendency of patients to take initial improvements in daytime sleepiness for granted as 
